Kornimate/medical-research-clean huggingface dataset:
stress and sleep study

Conditions: Stress, Psychological; Sleep; Transcutaneous Electric Nerve Stimulation; Vagus Nerve Stimulation; Mindfulness

Summary: this between-subject, longitudinal pilot study in healthy college students aims to explore the acceptability and preliminary outcomes of two novel and complementary interventions that may improve stress and sleep: transcutaneous vagus nerve stimulation (tvns) and a mobile mindfulness intervention.


Eligibility criteria:
inclusion criteria: * undergraduate student (ages 18-30) * must own a smartphone * must be able to read and write english exclusion criteria: * major medical illnesses including diagnosed severe neurological illnesses (e.g., stroke, seizure history), medical conditions associated with neurological effects (e.g. heart, kidney disease), autoimmune disorders, and severe psychiatric diseases (e.g., schizophrenia) * pregnancy * history of brain surgery, tumor, intracranial metal implantation, pacemakers or other implanted devices * history of adverse reaction to electrical nerve stimulation * prescribed sleep medications and/or psychotropic medications * illicit or prescription drug abuse within the last two months (marijuana or alcohol abuse \>2 weeks out will be acceptable for inclusion)
effects of pneumoperitoneum on dynamic alveolar stress-strain in anesthetized pediatric patients

Conditions: Atelectasis

Summary: general anesthesia is associated with loss of pulmonary functional residual capacity and consequent developement of atelectasis and closure of the small airway. infants and young children are more susceptible to this lung collapse due to their small functional residual capacity. mechanical ventilation in a lung with reduced functional residual capacity and atelectasis increased the dynamic alveolar stress-strain inducing a local inflammatory response in atelectatic lungs areas know as ventilatory induced-lung injury (vili). this phenomenon may appear even in healthy patients undergoing general anesthesia and predisposes children to hypoxemic episodes that can persist in the early postoperative period. during laparoscopy, pneumoperitoneum may aggravate the reduction of functional residual capacity as it generates a further increase in intra-abdominal pressure. the increase in alveolar stress-strain cloud be reduced during pneumoperitoneum in theory, if normal functional residual capacity is restored and the transpulmonary pression is reached at the end of expiration of 0-1 cmh2o.

this is a prospective and observational study designed to measure transpulmonary pressure during pneumoperitoneum. the investigators will studied 20 mechanically ventilated pediatric patients schedule for abdominal laparoscopy surgery under general anesthesia. lung mechanics will be assessed during laparoscopy. esophageal pressure will be measured by an esophageal ballon to measure transpulmonary pressure. lung collapse will detected when transpulmonary pressure became negative and using lung ultrasound images. a lung recruitment maneuver will be applied if these patients present atelectasis during surgery. the optimal level of positive end-expiratory pressure (peep) if defined as the peep level when transpulmonary pressure remains positive during the peep titration trial of the recruitment maneuver.

Eligibility criteria:
inclusion criteria: * written inform consent by parents * programmed surgery * laparoscopic surgery * supine position * american society of anesthesiologists classification: physical status i-ii exclusion criteria: * acute airway infection * cardiovascular or pulmonary disease

Keywords: children ultrasound
neladalkib (nvl-655) for tki-naive patients with advanced alk-positive nsclc

Conditions: Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase-positive

Summary: multicenter, randomized, controlled, open-label, phase 3 study designed to demonstrate that neladalkib (nvl-655) is superior to alectinib in prolonging progression-free survival (pfs) in patients with treatment-naïve, anaplastic lymphoma kinase (alk) positive, advanced non-small cell lung cancer (nsclc).

patients will be randomized in a 1:1 ratio (approximately 225 in each arm) to receive either neladalkib (nvl-655) or alectinib.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed locally advanced (not amenable for multimodality treatment) or metastatic non-small cell lung cancer (nsclc) 2. documented anaplastic lymphoma kinase (alk) rearrangement via testing of tissue or blood 3. no prior systemic anticancer treatment for nsclc (adjuvant/neoadjuvant chemotherapy allowed if 12 months prior to randomization; prior alk tyrosine kinase inhibitor \[tki\] such as alectinib is not allowed in any setting) 4. measurable disease (1 or more target lesions per response evaluation criteria in solid tumors \[recist\] 1.1) 5. pretreatment tumor tissue (archived or a fresh biopsy) 6. eastern cooperative oncology group (ecog) 0, 1 or 2 exclusion criteria: 1. patient's cancer has a known oncogenic driver alteration other than alk. 2. known allergy/hypersensitivity to excipients of neladalkib or alectinib. 3. ongoing or recent radiotherapy as per protocol-specified timeframes prior to randomization 4. major surgery within 4 weeks prior to randomization 5. uncontrolled clinically relevant infection requiring systemic therapy 6. known active tuberculosis, or active hepatitis b or c 7. qt corrected for heart rate by fridericia's formula (qtcf) \> 470 msec on repeated assessments 8. clinically significant cardiovascular disease 9. brain metastases associated with progressive neurological symptoms or requiring increasing doses of corticosteroids to control cns disease 10. active malignancy requiring therapy within 2 years prior to randomization

Keywords: nsclc lung cancer lung neoplasms lung diseases alk positive nsclc tki naive alk tki naive treatment naive
noninvasive assessment of neuronal damage by mri sodium ( 23na ) in amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: amyotrophic lateral sclerosis (als) is a neurodegenerative disease affecting the central and peripheral motor neurons, characterized by the rapidity of its evolution (median survival of 3 years). the pathophysiology of the disease is still poorly understood. neuronal death results from several cellular mechanisms entangled, including mitochondrial dysfunction. the absence of diagnostic marker causes a significant delay in diagnosis, on average a year. on the other hand, the wish biomarker is important for therapeutic trials. recently, mri sodium (23na) demonstrated its importance to detect noninvasively sodium accumulations associated with neuronal suffering. this neuronal pain can be caused by mitochondrial dysfunction causing the accumulation in the sodium and calcium cell causing neuronal death. these studies were conducted in multiple sclerosis, alzheimer's disease, huntington's disease, stroke and brain tumors. they demonstrated that sodium mri could be an effective and sensitive biomarker for detecting and quantifying neuronal degeneration. the goal of this study is to assess neuronal damage noninvasively by mri sodium in amyotrophic lateral sclerosis.


Eligibility criteria:
inclusion criteria: * amyotrophic lateral sclerosis patient according to the el escorial criteria revised brooks et al. 2000 bulbar or spinal beginning exclusion criteria: * patient or healthy volonteer presenting mri contre indications to this exam. * patient or healthy volonteer presenting severe high blood pressure undergoing medication to treat it or not. * patient or healthy volonteer having chronic psychiatric illness, dementia
the effect of nandrolone decanoate and leucine on muscle loss

Conditions: Muscle Atrophy

Summary: a decrease in muscle mass can have a profound impact on quality of life, as it can lead to decreased strength, insulin resistance, lower basal metabolic rate and obesity. with this study we investigate whether ingesting leucine or getting a nd injection will reduce the loss of muscle mass and strength.


Eligibility criteria:
inclusion criteria: * healthy men 18-35 years * bmi between 18.5 and 30 kg/m2 exclusion criteria: - (family) history of thromboembolic events * smoking * recent surgery (within 6 months prior to the study) * performing progressive resistance training more than three times per week in the past year * any back/leg/knee/shoulder complaints which may interfere with the use of crutches * current systemic use of corticosteroids, anabolic steroids, growth hormone, testosterone, nandrolone, protein supplements, immunosuppressants or insulin, blood sugar decreasing medication or epo * all co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis) * use of anti-coagulants * pre-existing renal disease or those with a potential risk for renal dysfunction (diabetes, hypertension, reduced glomerular filtration rate) * liver disease * heart failure * migraine * allergy to nuts or soy * high blood pressure (\>140 mmhg systolic and \>90 mmhg diastolic) in case of doubt, in- or exclusion of subject will be discussed with responsible physician or principal investigator.
predictive value of preoperative evaluation in cases of recurrent endometriosis

Conditions: Endometriosis

Summary: to investigate the effect of preoperative evaluation parameters in predicting recurrent disease in women who have undergone cystectomy or unilateral salpingo-oophorectomy due to endometriosis.

endometriosis is an estrogen-dependent gynecological disease characterized by the presence of endometrial-like tissue outside the uterine cavity, associated with pelvic pain and subfertility. despite its benign character, endometriosis can recur after surgery and continues to be a disease that disrupts the quality of life of millions of women. this study aimed to examine the risk factors in women who underwent cystectomy or unilateral salpingo-oophorectomy due to endometriosis but had a recurrence. therefore, the predictive value of parameters such as preoperative biochemical parameters, cyst size and the revised american society for reproductive medicine (rasrm) scoring system will be examined in recurrent cases.

Eligibility criteria:
inclusion criteria: * women aged 18-50 who had a cystectomy or unilateral oophorectomy due to endometriosis exclusion criteria: * women who have had bilateral oophorectomy due to endometriosis * malignant conditions * smoking * women with autoimmune disease

Keywords: endometriosis prevention & control preoperative procedures
effects of low-level laser therapy after surgical removal of impacted lower third molar

Conditions: Facial Swelling; Pain; Trismus

Summary: goal: the aim of this study was to evaluate the effects of low-level laser (lll) after surgical removal of impacted lower third molars (iltm).

goal: the aim of this study was to evaluate the effects of low-level laser (lll) after surgical removal of impacted lower third molars (iltm), including pain level, postoperative facial swelling, trismus and non-stimulated saliva secretory immunoglobulin a (siga).

Eligibility criteria:
inclusion criteria: * had two impacted lower third molars symmetrically in the same position as the classifications of pell- gregory and winter diagnosed by 2d panoramic radiography exclusion criteria: * patients with systemic diseases such as cardiovascular disease, hypertension, diabetes mellitus, pregnant, local infections * refused to participate in the study * patients who did not follow-up visit would be excluded
teams engaged in accessible mental health interventions for lupus erythematosus and dermatomyositis stress

Conditions: Lupus; Dermatomyositis, Juvenile; Dermatomyositis; Lupus Erythematosus; Lupus Erythematosus, Systemic; Lupus or SLE

Summary: the objectives of this study are to determine if the 'teams engaged in accessible mental health interventions for lupus erythematosus and dermatomyositis stress' (team-leads) intervention is feasible and acceptable to adolescents and young adults with lupus and dermatomyositis and whether it can help reduce stress and promote cardiovascular health behaviors in these individuals.


Eligibility criteria:
inclusion criteria: * diagnosis of juvenile-onset systemic lupus erythematosus (jsle) or dermatomyositis (jdm) * age 12-22 years old at time of enrollment exclusion criteria: * inability to complete surveys/interviews reliably * lack of access to internet-enabled device; * non-jsle/jdm diagnosis * history of myocardial infarction or cerebrovascular accident * evidence of severe emotional distress defined as any of the following at time of screening: a) patient health questionnaire for adolescents (phq9a) score ≥ 15 indicating severe depression; b) phq9a suicidality item score \> 0 indicating presence of any suicidal ideation; c) any other evidence noted of severe emotional distress per pi's judgment.

Keywords: stress depression anxiety lupus dermatomyositis pediatric rheumatology physical activity diet quality sleep cardiovascular health health behaviors remote intervention online intervention co-design intervention refinement
effectiveness of a cloud-based digital health navigation program for colorectal cancer screening

Conditions: Colorectal Cancer Screening

Summary: mpath-crc (mobile patient technology for health) is an automated direct-to-patient digital health program about colorectal cancer screening. the goal of this project is to test a cloud-based version of mpath that patients can use at home independent of a scheduled medical visit. patients will access mpath on their own devices using a hyperlink sent via text message. the cloud version of mpath will have the proven effective content of the tablet version, including the ability to request a screening test directly via the program. mpath will then share this information with the patient's healthcare organization so screening can be arranged. this cloud-based version will be highly scalable, have broad reach, and be easy to support, making it a commercially viable product. this project will (1) test the reach and effectiveness of the mpath web app in two different healthcare settings: a fee-for-service setting, and a value-based care setting; and (2) determine the value generated by mpath in each healthcare setting.


Eligibility criteria:
inclusion criteria: 1. age 45-74 years 2. be identified in the electronic health record as due for routine crc screening, defined as 1. no colonoscopy in prior 10 years 2. no flexible sigmoidoscopy in prior 5 years 3. no ct colography in prior 5 years 4. no fit-dna test (cologuard) within prior 3 years 5. no fecal occult blood test within prior 1 year 3. have a cell phone number listed in the ehr 4. have a preferred language of english or spanish in the ehr 5. upcoming appointment within 9 to 16 days 6. georgia market only: insurance type is listed as medicare advantage. exclusion criteria 1. prior diagnosis of colorectal cancer 2. prior history of total colectomy 3. currently enrolled in palliative care or hospice 4. age over 65 and currently enrolled in an institutional snp (i-snp) or living in long term care 5. age over 65 with frailty and advanced illness (as defined by the health system's my panel metric which mirrors the hedis col-e quality metric for crc screening)
a comparison of two nebulisers for sputum induction

Conditions: Asthma; COPD

Summary: sputum induction is considered a relatively non-invasive, reliable procedure, which can be utilised to characterise the inflammatory profile of the airways. however, the procedure can be slightly uncomfortable for patients. this study aims to assess the differences in participants' tolerability of sputum induction, by comparing two different nebulisers when performing the procedure.

this is a single centre, crossover study to compare the use of two nebulisers in the sputum induction procedure. 54 participants with stable asthma or copd will be recruited and will attend 2 visits, at least 48 hours apart. differences in the quality and quantity of samples and the time taken to produce a sample will be described. the main purpose is to explore the optimum device to perform the procedure, whilst protecting the safety of participants and maximising their comfort. if participants are unable to produce a sputum sample after completion of the induction procedure, physiotherapy techniques may be performed. this is an exploratory objective to establish whether these techniques may help in the event of unsuccessful procedures.

Eligibility criteria:
inclusion criteria: * have an ability to provide fully informed consent. * have a diagnosis of asthma or copd. * male or female. * age between 18 to 75 years. exclusion criteria: * have a post bronchodilator forced expiratory volume in the first second of less than 1 litre or less than 50 percent of the predicted value. * have an exacerbation of asthma or copd within the 30 days prior to the first visit. * have a history or current evidence of an upper or lower respiratory infection, within the 30 days prior to the first visit. * have any other clinically significant medical disease or uncontrolled concomitant disease, that is likely, in the opinion of the investigators to impact on the ability to participate in the study.

Keywords: asthma copd nebuliser sputum induction safety tolerability quality quantity physiotherapy
collagen injections for the treatment of acne scars and wrinkles

Conditions: Acne Scars; Wrinkles

Summary: the purpose of this study is to find out if autologous (your own) fibroblast injections are effective for the treatment of acne scars and wrinkles.


Eligibility criteria:
inclusion criteria: * age 18 or over * bilateral acne scars or have moderate to severe wrinkles * subjects in good health * subjects has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator exclusion criteria: * under 18 years of age * pregnancy or lactation * recent accutane use in the past 6 months * prone to hypertrophic and keloidal scarring * have excessively redundant skin in the treatment area or wrinkles longer than 20 cm total * have a history of autoimmune disorders, organ transplantation, cancer not in remission, active or chronic skin disease * have a history of basal-cell carcinoma * have previously received autologous fibroblast treatment * have undergone any confounding therapy in the lower two-thirds of the face within 1 year or any investigational treatment within 30 days. * have an allergy to collagen, bovine products, local anesthetics, gentamicin, or amphotericin b * subjects who are unable to understand the protocol or to give informed consent * subjects with mental illness
high-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer: long-term follow-up

Conditions: Breast Cancer Female

Summary: collection of follow-up data from the original trial patient cohort.

collection of follow-up data from the original trial patient cohort by means of structured patient file abstraction, a questionnaire to the general practitioner, and registry consultations.

Eligibility criteria:
inclusion criteria: * enrolment in the original trial. exclusion criteria: * none.
effect of ramadan fasting on kidney function and proteinuria in patients with glomerulonephritis

Conditions: Fasting Ramadan

Summary: this research aims to assess effects of ramadan fasting on kidney function and proteinuria in patients with glomerulonephritis.

fasting from sunrise to sunset during the islamic holy month of ramadan is one of the five pillars of the islamic faith. duration of the fasting ranges from 10 to 18 hours per day according to the geographic location and the season. although people with chronic illnesses are exempted from fasting according to islamic beliefs, many patients insist on fasting against medical advice. through the last three decades many reports studied the potential risks and benefits of fasting ramadan in regular hemodialysis (hd) patients. target points of investigation were different. most of them were focusing on the electrolytes and nutritional changes. fewer reports tested the mortality rate. in a multicenter observational study, 2055 egyptian patients from 25 hd units were studied for frequency of fasting in ramadan and the possible effect of fasting on clinical and biochemical variables. the investigators concluded that nearly 47% of the study patients fasted at least few days of ramadan. they recommended that hd patients should be encouraged to discuss the option of fasting in ramadan with their hd staff who might be able to give advice on whether to allow them to fast in days off dialysis with special precautions regarding associated comorbidities, especially diabetes and coronary artery disease. most of the studies focused on the effects of fasting the month of ramadan in ckd and hemodialysis patients, but no research assessed these effects specifically in patients with glomerulonephritis.

Eligibility criteria:
inclusion criteria: * patients with biopsy proven glomerulonephritis with egfr ≥ 30 ml/min for more than 3 months (exception is nephrotic patients with positive anti-pla2r indicative of primary membranous). exclusion criteria: * patients with medical contraindications for fasting. * patients with egfr \< 30 ml/min. * patients with acute cardiovascular disease. * uncontrolled diabetes mellitus. * active or chronic inflammatory disease. * acute liver disease. * pregnancy.

Keywords: fasting ramadan glomerulonephritis kidney functions